Welcome, Guest. Please login or register.
July 23, 2024, 11:48:10 pm

Login with username, password and session length


Members
Stats
  • Total Posts: 774147
  • Total Topics: 66458
  • Online Today: 3300
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 2
Guests: 3138
Total: 3140

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Biktarvy as Post-Exposure Prophylaxis  (Read 4667 times)

0 Members and 1 Guest are viewing this topic.

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 22,707
  • Threads: @jim16309
    • Social Media: Threads
Biktarvy as Post-Exposure Prophylaxis
« on: April 04, 2024, 05:37:18 am »
POZ.com article in full: https://www.poz.com/article/biktarvy-can-good-option-postexposure-prophylaxis

In brief:

Quote
The once-daily Biktarvy pill, widely used for HIV treatment, can also be a good option for post-exposure prophylaxis (PEP), according to study results presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) in Denver.

The new study included 120 people who received PEP at emergency departments. Participants who initiated PEP with another regimen were switched to Biktarvy for the remainder of the 28 days. Most (89%) had initially been prescribed dolutegravir plus TDF/FTC, two started on raltegravir plus TDF/FTC and 11 started on Biktarvy.

The researchers found that adherence to Biktarvy PEP was high: 88% of the participants with available data reported that they took PEP for at least 28 days. Twelve people stopped PEP early, mostly after 20 days. PEP was generally well tolerated.

No HIV seroconversions occurred among the 66 participants who were tested for HIV at 12 weeks. Nearly a quarter went on to start PrEP by their final study visit.

Biktarvy PEP “was safe, well tolerated and associated with high adherence and no HIV seroconversions,” showing that this is an appropriate single-tablet integrase inhibitor-based HIV PEP regimen, the researchers concluded.

HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

My Instagram
Threads

Offline numbersguy82

  • Member
  • Posts: 592
  • Adrian Alan
    • Instagram
Re: Biktarvy as Post-Exposure Prophylaxis
« Reply #1 on: April 04, 2024, 10:15:42 am »
Interesting. I wonder if this designation would make the price of Biktarvy go up or down, for the regular user.
Peer Support is returning, every THIRD Thursday beginning in July. New Time, New Day, New Format!

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 22,707
  • Threads: @jim16309
    • Social Media: Threads
Re: Biktarvy as Post-Exposure Prophylaxis
« Reply #2 on: April 04, 2024, 03:06:26 pm »
Interesting. I wonder if this designation would make the price of Biktarvy go up or down, for the regular user.

I honestly don't know, part of me would not expect anything to get cheaper. I wonder if the prices changed in the past when newer drugs were approved for PEP? Maybe someone knows.
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

My Instagram
Threads

 


Terms of Membership for these forums
 

© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.